LIQUIDITY (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|---|
Nov. 30, 2021 |
Oct. 31, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2019 |
|
| Net loss | $ (12,593) | $ (7,097) | $ (20,429) | $ (10,717) | $ 20,900 | ||||
| Net cash used in operating activities | (13,538) | $ (9,814) | 20,400 | ||||||
| Accumulated deficit | (188,567) | (188,567) | (168,138) | ||||||
| Cash and cash equivalents | 77,403 | 77,403 | 41,047 | $ 77,403 | $ 37,600 | ||||
| Current liabilities | $ 6,445 | 6,445 | $ 1,968 | ||||||
| Net proceeds from the offering | $ 52,300 | $ 52,300 | |||||||
| Gross proceeds from sale of equity | 2,700 | ||||||||
| Underwritten Offering | |||||||||
| Net proceeds from the offering | 47,300 | 47,300 | |||||||
| Registered Direct Offering [Member] | |||||||||
| Net proceeds from the offering | $ 5,000 | $ 5,000 | |||||||
| Phase 2 Clinical Trial RZ402 | |||||||||
| Milestone closing payment | 3,000 | ||||||||
| Phase 2 Clinical Trial RZ358 | |||||||||
| Milestone closing payment | $ 2,000 | ||||||||
| X | ||||||||||
- Definition Amount of milestone payment made during the period. No definition available.
|
| X | ||||||||||
- Definition Amount of net proceeds from the offering. No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|